Endocrine and metabolic complications of COVID-19: lessons learned and future prospects

J Mol Endocrinol. 2022 Aug 24;69(3):R125-R150. doi: 10.1530/JME-22-0036. Print 2022 Oct 1.

Abstract

Coronavirus disease 2019 (COVID-19) is well known for its respiratory complications; however, it can also cause extrapulmonary manifestations, including cardiovascular, thrombotic, renal, gastrointestinal, neurologic, and endocrinological symptoms. Endocrinological complications of COVID-19 are rare but can considerably impact the outcome of the patients. Moreover, preexisting endocrinologic disorders can affect the severity of COVID-19. Thyroid, pancreas, adrenal, neuroendocrine, gonadal, and parathyroid glands are the main endocrinologic organs that can be targeted by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Endocrinological complications of COVID-19 are rare but can significantly deteriorate the patients' prognosis. Understanding the interaction between COVID-19 and the endocrine system can provide a potential treatment option to improve the outcome of COVID-19. In this article, we aim to review the short-term and long-term organ-based endocrinological complications of COVID-19, the pathophysiology, the influence of each complication on COVID-19 prognosis, and potential therapeutic interventions based on current published data. Moreover, current clinical trials of potential endocrinological interventions to develop therapeutic strategies for COVID-19 have been discussed.

Keywords: complications; coronavirus disease 2019 (COVID-19); endocrine; metabolism; severe acute respiratory syndrome coronavirus disease-2 (SARS-CoV-2).

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • Endocrine Glands*
  • Humans
  • Nervous System
  • SARS-CoV-2